Martin Fridson
-
When Ecstasy Turns To Agony
In looking at the distressed-bond market today, Marty Fridson suggests: Fasten your seatbelts. It’s going to get very bumpy. But investors who remain rational will profit extravagantly from the foreseeable disconnect between value and price in the lower-quality end of the corporate bond market.
-
A Second Life For An American Icon
Investors are concerned that the products of the company featured this month are on the wrong side of history and condemned to permanent decline. This report will explain how the company is reinventing itself – and will remain a survivor – and propelling the price of its bond higher.
-
Opioids, Bankruptcies, And The U.S. Supreme Court
As distressed-debt analysts, we have to keep tabs on the developments with the bankruptcy code. Typically, our most likely case is that the bond issuer will manage to make all the required interest payments and repay the principal at maturity. But not always.
-
Investing With A Titan
This month’s recommendation reminds us of our very first recommendation in March 2023, when we wrote about Diversified Healthcare Trust’s 9.75% bonds. We believe that in both cases, investors were looking backward rather than forward, creating an opportunity for high, risk-adjusted returns.
-
Guilty Until Proven Innocent
Many beaten-down bonds deserve to be beaten down and never to recover. A smaller number of issuers, also beaten down, do have the wherewithal to make good on their obligations and strengthen their balance sheets.